Explore These Critical Case Reviews:
- Frontline Metastatic Colorectal Cancer: Unresectable Liver Metastases
- Frontline Metastatic Colorectal Cancer: Resectable Liver Metastases
- Adjuvant Treatment for Colorectal Cancer: Stage II
- Refractory Colorectal Cancer
Educational Objectives
After participating in this program, participants should be able to:
- Review the cases of patients with different stages of colorectal cancer in order to aid the community-based oncologist in demonstrating the decision-making process that goes into the formulation of evidence-based treatment plans.
- Incorporate the new standard in adjuvant treatment for stage III disease and be aware of the evidence of benefit of adjuvant treatment for stage II disease.
- Appraise all treatment options for patients with advanced colorectal cancer. Because the selected initial therapy influences the sequence of treatment regimens, special consideration must be taken in finding the appropriate first step in the medical management of advanced colorectal cancer.
- Demonstrate knowledge of variables related to comorbidities, prior toxicities, and the initial response or lack of response to the first-line approach in the selection of second-line treatments.
- Demonstrate knowledge variables that go into dosing and possible toxicities that colorectal cancer patients may face from chemotherapy and ways to counteract these effects.
Who Will Benefit
Community-based oncologists, hematologists/oncologists, nurse practitioners and nurses.
Financial Disclosures
Dr. Marshall has received research support from Genentech, Pfizer, Amgen, Roche, Bristol-Myers Squibb, and Boehringer-Ingelheim; has served on speakers bureaus for Roche, Pfizer, sanofi-aventis, Genentech, and Bristol-Myers Squibb; and is a consultant for Boehringer Ingelheim. Dr. Grothey has received honoraria from sanofi-aventis, Genentech, Amgen, Roche, and Bristol-Myers Squibb, as well as research support from sanofi-aventis. Dr. Choti has acted as a consultant for sanofi-aventis and a speaker for sanofi-aventis and Genentech. Dr. Blackstock has received research support from and served on advisory boards for sanofi-aventis. Eli Lilly, Protherics, and Genentech; he has received research support from Merck, AstraZeneca, and Boston Scientific.
Participants' financial disclosure information will be made available prior to the activity.
